Skip to content
Three questions men can ask about prostate cancer
Prostate cancer is the most common solid cancer among men, with 1 in 8 men being diagnosed in their lifetime and 1 in 44 […]
Three questions men can ask about prostate cancer Read More »
Life sciences job report shows growth slowing, but firms still invest in talent
As the United States has long been a life sciences leader, the health of the life sciences sector is a pretty good indicator of
Life sciences job report shows growth slowing, but firms still invest in talent Read More »
BIO 2025: The urgent need to address AMR and cancer
As antimicrobial resistance (AMR) continues to threaten global public health, its impact on cancer patients is a growing, often overlooked crisis. Patients with cancer
BIO 2025: The urgent need to address AMR and cancer Read More »
BIO 2025: The innovation race vs. the regulatory pace
We often talk about the exciting jumps in technology and innovation that improve and save lives. What is less frequently discussed is how regulation
BIO 2025: The innovation race vs. the regulatory pace Read More »
Alzheimer’s Awareness Month: What to know about a disease impacting millions
Over 7 million Americans live with Alzheimer’s disease, according to the Alzheimer’s Association. For June’s Alzheimer’s Awareness Month, Bio.News sat down with the Alzheimer’s
Alzheimer’s Awareness Month: What to know about a disease impacting millions Read More »
BIO 2025: What is the PRV program and why does it matter?
Established in 2012, the Pediatric Priority Review (PPRV) program offers a powerful incentive for companies to develop treatments for rare conditions affecting children. Even
BIO 2025: What is the PRV program and why does it matter? Read More »
BIO 2025: ‘Behind every data point there is a person’
The 2025 Biotechnology Innovation Organization (BIO) International Convention highlighted why we – the biotech industry – do what we do. In one word: patients.
BIO 2025: ‘Behind every data point there is a person’ Read More »
BIO 2025: Rare disease patients can’t wait
The rare disease patient community is the beating heart of the Biotechnology Innovation Organization’s (BIO) mission. Whether it is driving policy that supports innovation,
BIO 2025: Rare disease patients can’t wait Read More »
BIO 2025: Commissioner Martin Makary, M.D., M.P.H., discusses vision for FDA
Food and Drug Administration (FDA) Commissioner Martin A. Makary, M.D., M.P.H., sat down with the Biotechnology Innovation Organization (BIO) President and CEO John F.
BIO 2025: Commissioner Martin Makary, M.D., M.P.H., discusses vision for FDA Read More »
BIO 2025: How do we talk about vaccines now?
Public health advocates are reevaluating the vaccine landscape, revisiting long-held assumptions about vaccine policy during both public health emergencies and periods of relative calm.
BIO 2025: How do we talk about vaccines now? Read More »